Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 17/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | RXRA | P19793 | 1/20 | 0.52 |
| ▸ | RXRB | P28702 | 1/20 | 0.52 |
| ▸ | RXRG | P48443 | 1/20 | 0.52 |
| ▸ | ACLY | P53396 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1756460 | 0.83 | PTGER4 (1.00) | PTGER4 | |
| SCHEMBL1756403 | 0.80 | POLB (0.55) | NPC1KDM4ELMNAPOLBHSD17B10 | |
| SCHEMBL3535149 | 0.78 | PTGER4 (0.84) | PTGER4 | |
| SCHEMBL3541851 | 0.77 | PTGER4 (0.82) | PTGER4 | |
| SCHEMBL3538451 | 0.77 | PTGER4 (1.00) | PTGER4POLBHSD17B10TDP1L3MBTL1 | |
| SCHEMBL3535596 | 0.76 | PTGER4 (0.82) | PTGER4NPC1KDM4ELMNAPOLB | |
| SCHEMBL3543639 | 0.76 | PTGER4 (1.00) | PTGER4 | |
| SCHEMBL3534435 | 0.76 | PTGER4 (1.00) | PTGER4KDM4EPOLBHSD17B10TDP1 | |
| SCHEMBL1756402 | 0.75 | PTGER4 (0.85) | PTGER4KDM4EPOLBHSD17B10TDP1 | |
| SCHEMBL3536669 | 0.75 | PTGER4 (0.81) | PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039495-B2 | Biphenyl carboxylic acids and bioisosteres as glycogen synthase activators | HOFFMAN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| WO-2011067174-A1 | ANILINE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067266-A1 | CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-06-09 | — | — | US | disclosed |
| US-20110130438-A1 | ANILINE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-06-02 | — | — | US | disclosed |
| US-7947728-B1 | Indole and indazole analogs as glycogen synthase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-24 | — | — | US | disclosed |
| WO-2011058154-A1 | BIPHENYL CARBOXYLIC ACIDS AND BIOISOSTERES AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011057993-A1 | INDAZOLONE DERIVATIVES AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011057956-A1 | BENZISOXAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20110118314-A1 | PIPERIDINE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | YUN WEIYA | 2011-05-19 | — | — | US | disclosed |
| US-20110118322-A1 | BIPHENYL CARBOXYLIC ACIDS AND BIOISOSTERES AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-19 | — | — | US | disclosed |
| WO-2011058122-A1 | PIPERIDINE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011057959-A1 | INDOLE AND INDAZOLE DERIVATIVES AS GLYCOGEN SYNTHASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20110112147-A1 | INDAZOLONE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-12 | — | — | US | disclosed |
| US-20110112161-A1 | INDOLE AND INDAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-12 | — | — | US | disclosed |
| US-20110112158-A1 | BENZISOXAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-05-12 | — | — | US | disclosed |
| US-7939569-B1 | Aniline analogs as glycogen synthase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112161-A1 | INDOLE AND INDAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, PYGL, GSK3B | PTGER4 2663/4885NPC1 2340/4885KDM4E 2609/4885 |
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | PTGER4 3583/4885NPC1 2219/4885KDM4E 2984/4885 |
| US-20110118322-A1 | BIPHENYL CARBOXYLIC ACIDS AND BIOISOSTERES AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | PTGER4 3524/4885NPC1 1924/4885KDM4E 3393/4885 |
| US-20110130438-A1 | ANILINE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, PYGL, GYS1 | PTGER4 3495/4885NPC1 2526/4885KDM4E 2700/4885 |
| US-20110112158-A1 | BENZISOXAZOLE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | PTGER4 2754/4885NPC1 2403/4885KDM4E 2621/4885 |
| US-20110118314-A1 | PIPERIDINE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | PTGER4 2295/4885NPC1 2182/4885KDM4E 1989/4885 |
| US-20110112147-A1 | INDAZOLONE ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | PTGER4 3017/4885NPC1 1493/4885KDM4E 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.